S100A12 was also significantly increased early in both the plasma and BAL of ARDS patients (days 0–3) and remained elevated in plasma for up to 90–180 days (Figure 5A), and in BAL fluid for up to 15–21 days (Figure 5B). This evidence concerns the gene S100A12 and acute respiratory distress syndrome.